Please assess the completion status of the following clinical trial:

Trial Title: Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Steroid dependent or refractory classic chronic GVHD disease.~* No more than 3 previous treatments for cGVHD.~* Receiving baseline systemic glucocorticoid therapy (at stable dose) for cGVHD at study entry.~* Men and women ≥18 years old.~* Karnofsky performance status ≥60.~Exclusion Criteria:~* Known or suspected active acute GVHD.~* Current treatment with sirolimus AND either cyclosporine or tacrolimus.~* History of treatment with a tyrosine kinase inhibitor (eg, imatinib), purine analogs or other cancer chemotherapy in the 4 weeks prior to starting study drug.~* Currently active, clinically significant cardiovascular disease.~* Uncontrolled infections not responsive to antibiotics, antiviral medicines, or antifungal medicines or a recent infection requiring systemic treatment that was completed ≤14 days before the first dose of study drug.~* Progressive underlying malignant disease including post-transplant lymphoproliferative disease.~* History of other malignancy (not including the underlying malignancy that was the indication for transplant)~* Concomitant use of warfarin or other Vitamin K antagonists~* Known bleeding disorders or hemophilia.~* History of stroke or intracranial hemorrhage within 6 months prior to enrollment.~* Known history of human immunodeficiency virus (HIV) or active with hepatitis C virus (HCV) or hepatitis B virus (HBV).~* Concurrent use of a strong cytochrome P450(CYP) 3A inhibitor.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1b: Dose Level 1 (Type: EXPERIMENTAL): Subjects receive daily dose of 420 mg of Ibrutinib capsules
- Phase 1b: Dose Level 2 (Type: EXPERIMENTAL): Subjects receive daily dose of 280 mg of Ibrutinib capsules
- Phase 1b: Dose Level 3 (Type: EXPERIMENTAL): Subjects receive daily dose of 140 mg of Ibrutinib capsules
- Phase 2 (Type: EXPERIMENTAL): Subjects receive daily dose of recommended phase 2 dose

Based on this trial design, predict the completion outcome and termination type (if applicable).